{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-25-000076","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.100371+00:00","generated_at":"2026-05-17T00:02:30.484990+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zymeworks Q3 2025 revenue $27.6M, net loss narrows to $19.6M; positive ZW191 data","bullets":["Revenue $27.6M (up from $16.0M YoY) driven by $25.0M J&J milestone; net loss $19.6M vs $29.9M.","Cash resources $299.4M as of Sep 30, 2025; projected runway into 2H-2027 including anticipated milestones.","Encouraging Phase 1 data for ZW191 (FRα ADC): 53% objective response rate (64% in gynecological cancers).","First patient dosed in Phase 1 trial of ZW251 (GPC3-targeting ADC) for hepatocellular carcinoma.","Completed $22.7M in share repurchases (1.44M shares at avg $15.80) under remaining $30.0M program."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-25-000076","json":"https://secwatch.observer/filing/0001937653-25-000076.json","markdown":"https://secwatch.observer/filing/0001937653-25-000076.md","text":"https://secwatch.observer/filing/0001937653-25-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765325000076/0001937653-25-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765325000076/zyme-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:02:30.484990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}